Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01306110

Acronym

DIABSCAN

Enrollment

277

Registered

2011-03-01

Start date

2007-06-30

Completion date

2010-12-31

Last updated

2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

Liver fibrosis, diabetes, Fibroscan, Fibrotest, noninvasive fibrosis biomarkers

Brief summary

The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.

Detailed description

Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female subjects * More than 18 years of age * Patients with Diabetes * Written informed consent

Exclusion criteria

* Patients refusing to participate to the study and to provide written informed consent

Countries

France

Outcome results